https://survivinsignaling.com/....index.php/use-of-int
The report describes long-term patient outcomes in small, node-negative, HER2-positive breast cancer following adjuvant paclitaxel and trastuzumab therapy, with the aim of finding prospective biomarkers for prognosis. In this phase 2, single-arm, open-label trial, participants were recruited from 16 institutions spread across 13 American cities to evaluate patients aged 18 and above, harboring small (3 cm), node-negative, HER2-positive breast cancers, a
Aimer
Commentaire
Partagez
